바이오테크 보도자료
-
- Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis
- Galderma today announced that the Journal of the European Academy of Dermatology and Venereology (JEADV) has published full results from a post-hoc analysis of the phase 2b study of its investigational therapy, nemolizumab, in adult patients with ...
- 2021년 04월 08일
-
- Milestone Study Shows Natural Molecule, Urolithin A, Can Improve Muscle Function and Life Expectancy in Mice With Muscle Dystrophy
- Progression of Duchenne Muscle Dystrophy (DMD) can be delayed in mice by supplementing their diets with Urolithin A, according to new results reported today. The findings, published in Science Translational Medicine, raise hopes that new treatment...
- 2021년 04월 08일
-
- Humanigen Announces Closing of Public Offering of Common Stock
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that on April 5,...
- 2021년 04월 07일
-
- NuScale Power Secures $40 Million Investment, Support for SMR Deployment from JGC Holdings Corporation
- NuScale Power today announced that it has finalized an investment and strategic partnership agreement with JGC Holdings Corporation (JGC HD), a holding company of the world's leading EPC contractor group companies headquartered in Japan. As part o...
- 2021년 04월 06일
-
- CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
- The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Nat...
- 2021년 04월 05일
-
- Takeda Hosts Wave 1 Pipeline Market Call
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio. With several NME...
- 2021년 04월 01일
-
- Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Orifarm Group (“Orifarm”) for a total value of up to $670 million USD. The po...
- 2021년 04월 01일
-
- Xlife Sciences AG (XLS): 2020 Financial Results
- In 2020, Xlife Sciences AG (XLS) significantly increased its profit to 21.2 million Swiss francs compared to the previous year (1.03 million). The increase is based on the transaction and the capital appreciation of the portfolio companies Velabs ...
- 2021년 04월 01일
-
- Takeda Completes Sale of Its Japan Consumer Health Care Business Unit to Blackstone
- Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer Healthcare Company Limited (“TCHC”) to Oscar A-Co KK, a company controlled by funds managed...
- 2021년 04월 01일
-
- Humanigen Announces Pricing of Public Offering of Five Million Shares of Common Stock
- Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has price...
- 2021년 04월 01일
-
- Humanigen Announces Proposed Public Offering of Five Million Shares of Common Stock
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumabTM, today announced that it has com...
- 2021년 03월 31일
-
- VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
- Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for difelikefa...
- 2021년 03월 30일
-
- Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced positive topline...
- 2021년 03월 30일
전시회
